Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs & Aging
Erschienen in: Drugs & Aging 6/2019

02.04.2019 | Review Article

Safety and Tolerability of Pharmacotherapies for Parkinson’s Disease in Geriatric Patients

verfasst von: Martin Klietz, Stephan Greten, Florian Wegner, Günter U. Höglinger

Erschienen in: Drugs & Aging | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Parkinson’s disease is a chronic neurodegenerative movement disorder affecting people mainly beyond their 50s. Geriatric patients with Parkinson’s disease experience a specific profile of comorbidities. Multimorbidity and resulting polypharmacotherapy are frequent at this age. Comorbid diseases, widely spread, involve arterial hypertension, ischemic heart disease, heart failure, atrial fibrillation, polyneuropathy, diabetes mellitus, cerebrovascular disease, sarcopenia, and frailty. Following years of drug development, levodopa is still the most effective drug for the treatment of motor symptoms. However, a wide range of other drugs are available with specific effects, contraindications, and complications. The treatment of geriatric patients with Parkinson’s disease is challenging and requires the cooperation of multidisciplinary teams. A careful assessment of a patient’s Parkinson’s disease symptoms, comorbidities, medication, vital signs, and resources is crucial for an effective and safe therapy. Laboratory tests can assist in the identification of contraindications for specific treatments. Identifying potentially inadequate drugs from prescription lists can lead to a better targeted treatment for geriatric patients with Parkinson’s disease. Future research should help develop a more evidence-based therapy of geriatric patients with Parkinson’s disease. For this purpose, randomized controlled trials of geriatric patients are urgently needed. An international register concerning issues of safer drug application and monitoring could help to implement a better treatment.
Literatur
1.
de Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5:525–35.CrossRefPubMed
2.
Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med. 2003;348:1356–64.CrossRefPubMed
3.
Politis M, Wu K, Molloy S, Bain PG, Chaudhuri KR, Piccini P. Parkinson’s disease symptoms: the patients perspective. Mov Disord. 2010;25:1646–51.CrossRefPubMed
4.
Forsaa EB, Larsen JP, Wentzel-Larsen T, Herlofson K, Alves G. Predictors and course of health-related quality of life in Parkinson’s disease. Mov Disord. 2008;23:1420–7.CrossRefPubMed
5.
Soh S-E, Morris ME, McGinley JL. Determinants of health-related quality of life in Parkinson’s disease: a systematic review. Parkinsonism Relat Disord. 2011;17:1–9.CrossRefPubMed
6.
Klietz M, Tulke A, Müschen LH, Paracka L, Schrader C, Dressler DW, et al. Impaired quality of life and need for palliative care in a German cohort of advanced Parkinson’s disease patients. Front Neurol. 2018;9:120.CrossRefPubMedPubMedCentral
7.
Kempster PA, O’Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson’s disease: a clinico-pathological study. Brain. 2010;133:1755–62.CrossRefPubMed
8.
Muller-Rebstein S, Trenkwalder C, Oertel WH, Culmsee C, Eckermann G, Höglinger GU. Pharmacotherapy of Parkinson’s disease: aspects of drug safety. Nervenarzt. 2017;88:888–94.CrossRefPubMed
9.
10.
Lingor P, Csoti I, Koschel J, Schrader C, Winkler C, Wolz M, et al. The geriatric patient with Parkinson’s disease: a neurological challenge. Fortschr Neurol Psychiatry. 2016;84(Suppl. 1):S41–7.
11.
Jakovljevic M, Ostojic L. Comorbidity and multimorbidity in medicine today: challenges and opportunities for bringing separated branches of medicine closer to each other. Psychiatr Danub. 2013;25(Suppl. 1):18–28.PubMed
12.
13.
Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380:37–43.CrossRefPubMed
14.
Hou JG, Wu LJ, Moore S, Ward C, York M, Atassi F, et al. Assessment of appropriate medication administration for hospitalized patients with Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:377–81.CrossRefPubMed
15.
McLean G, Hindle JV, Guthrie B, Mercer SW. Co-morbidity and polypharmacy in Parkinson’s disease: insights from a large Scottish primary care database. BMC Neurol. 2017;17:126.CrossRefPubMedPubMedCentral
16.
Choi J, Ahn A, Kim S, Won CW. Global prevalence of physical frailty by Fried’s criteria in community-dwelling elderly with national population-based surveys. J Am Med Dir Assoc. 2015;16:548–50.CrossRefPubMed
17.
Santos-Eggimann B, Cuenoud P, Spagnoli J, Junod J. Prevalence of frailty in middle-aged and older community-dwelling Europeans living in 10 countries. J Gerontol A Biol Sci Med Sci. 2009;64:675–81.CrossRefPubMed
18.
19.
Riedel O, Dodel R, Deuschl G, Förstl H, Henn F, Heuser I, et al. Dementia and depression determine care dependency in Parkinson’s disease: analysis of 1,449 outpatients receiving nursing care in Germany. Nervenarzt. 2011;82:1012–9.CrossRefPubMed
20.
Riedel O, Dodel R, Deuschl G, Klotsche J, Förstl H, Heuser I, et al. Depression and care-dependency in Parkinson’s disease: results from a nationwide study of 1449 outpatients. Parkinsonism Relat Disord. 2012;18:598–601.CrossRefPubMed
21.
Leibson CL, Maraganore DM, Bower JH, Ransom JE, O’Brien PC, Rocca WA. Comorbid conditions associated with Parkinson’s disease: a population-based study. Mov Disord. 2005;21:446–55.CrossRef
22.
Tönges L, Bartig D, Muhlack S, Jost W, Gold R, Krogias C. Characteristics and dynamics of inpatient treatment of patients with Parkinson’s disease in Germany: analysis of 1.5 million patient cases from 2010 to 2015. Nervenarzt. 2018;2018(16):552.
23.
Müller-Rebstein S, Trenkwalder C, Ebentheuer J, Oertel WH, Culmsee C, Höglinger GU. Drug safety analysis in a real-life cohort of Parkinson’s disease patients with polypharmacy. CNS Drugs. 2018;31:1093–102.CrossRef
24.
Balzer-Geldsetzer M, Ferreira J, Odin P, Bloem BR, Meissner WG, Lorenzl S, et al. Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study. BMC Neurol. 2018;18:185.CrossRefPubMedPubMedCentral
25.
Zesiewicz TA, Strom JA, Borenstein AR, Hauser RA, Cimino CR, Fontanet HL, et al. Heart failure in Parkinson’s disease: analysis of the United States Medicare current beneficiary survey. Parkinsonism Relat Disord. 2004;10:417–20.CrossRefPubMed
26.
Santiago JA, Bottero V, Potashkin JA. Biological and clinical implications of comorbidities in Parkinson’s disease. Front Aging Neurosci. 2017;9:394.CrossRefPubMedPubMedCentral
27.
Lai S-W, Lin C-L, Liao K-F, Chang-Ou K-C. Increased risk of Parkinson’s disease in cataract patients: a population-based cohort study. Parkinsonism Relat Disord. 2015;21:68–71.CrossRefPubMed
28.
Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson’s disease: a postmortem study. Acta Neuropathol. 2003;105:415–9.PubMed
29.
Hong CT, Hu H-H, Chan L, Bai C-H. Prevalent cerebrovascular and cardiovascular disease in people with Parkinson’s disease: a meta-analysis. Clin Epidemiol. 2018;10:1147–54.CrossRefPubMedPubMedCentral
30.
Ebersbach G, Sojer M, Muller J, Ransmayr G, Wenning G, Poewe W. Dysequilibrium in idiopathic Parkinson disease: the effect of cerebrovascular comorbidity. Nervenarzt. 2002;73:162–5.CrossRefPubMed
31.
Kotagal V, Albin RL, Muller MLTM, Koeppe RA, Studenski S, Frey KA, et al. Advanced age, cardiovascular risk burden, and Timed Up and Go Test performance in Parkinson disease. J Gerontol A Biol Sci Med Sci. 2014;69:1569–75.CrossRefPubMedPubMedCentral
32.
Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care. 2007;30:842–7.CrossRefPubMed
33.
Cereda E, Barichella M, Cassani E, Caccialanza R, Pezzoli G. Clinical features of Parkinson disease when onset of diabetes came first: a case–control study. Neurology. 2012;78:1507–11.CrossRefPubMed
34.
Kotagal V, Albin RL, Müller MLTM, Koeppe RA, Frey KA, Bohnen NI. Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord. 2013;19:522–6.CrossRefPubMedPubMedCentral
35.
Bohnen NI, Kotagal V, Müller MLTM, Koeppe RA, Scott PJH, Albin RL, et al. Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord. 2014;20:1394–8.CrossRefPubMedPubMedCentral
36.
Metta V, Sanchez TC, Padmakumar C. Osteoporosis: a hidden nonmotor face of Parkinson’s disease. Int Rev Neurobiol. 2017;134:877–90.CrossRefPubMed
37.
Deng Q, Zhou X, Chen J, Pan M, Gao H, Zhou J, et al. Lower hemoglobin levels in patients with Parkinson’s disease are associated with disease severity and iron metabolism. Brain Res. 2017;1655:145–51.CrossRefPubMed
38.
Wielinski CL, Erickson-Davis C, Wichmann R, Walde-Douglas M, Parashos SA. Falls and injuries resulting from falls among patients with Parkinson’s disease and other parkinsonian syndromes. Mov Disord. 2005;20:410–5.CrossRefPubMed
39.
Huang Y-F, Cherng Y-G, Hsu SPC, Yeh C-C, Chou Y-C, Wu C-H, et al. Risk and adverse outcomes of fractures in patients with Parkinson’s disease: two nationwide studies. Osteoporos Int. 2015;26:1723–32.CrossRefPubMed
40.
41.
Hornykiewicz O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord. 2002;17:501–8.CrossRefPubMed
42.
43.
44.
Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet. 1987;13:141–78.CrossRefPubMed
45.
Wood LD. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson’s disease. Drugs Aging. 2010;27:295–310.CrossRefPubMed
46.
Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16:448–58.CrossRefPubMed
47.
Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson’s disease? J Neurol. 2002;249:419–23.CrossRefPubMed
48.
Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial earlier vs later l-DOPA. Arch Neurol. 1999;56:529–35.CrossRefPubMed
49.
Olanow CW, Obeso JA, Stocchi F. Drug insight: continuous dopaminergic stimulation in the treatment of Parkinson’s disease. Nat Clin Pract Neurol. 2006;2:382–92.CrossRefPubMed
50.
Blanchet PJ, Grondin R, Bedard PJ, Shiosaki K, Britton DR. Dopamine D1 receptor desensitization profile in MPTP-lesioned primates. Eur J Pharmacol. 1996;309:13–20.CrossRefPubMed
51.
Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5:677–87.CrossRefPubMed
52.
Keber U, Klietz M, Carlsson T, Oertel WH, Weihe E, Schafer MKH, et al. Striatal tyrosine hydroxylase-positive neurons are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice. Neurosciene. 2015;298:302–17.CrossRef
53.
Klietz M, Keber U, Carlsson T, Chiu W-H, Höglinger GU, Weihe E, et al. l-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons. Neuroscience. 2016;331:120–33.CrossRefPubMed
54.
55.
Othman AA, Dutta S. Population pharmacokinetics of levodopa in subjects with advanced Parkinson’s disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. Br J Clin Pharmacol. 2014;78:94–105.CrossRefPubMedPubMedCentral
56.
Stocchi F, Vacca L, Stirpe P, Torti M. Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2018;14:1189–95.CrossRefPubMed
57.
58.
Weintraub D, Chiang C, Kim HM, Wilkinson J, Marras C, Stanislawski B, et al. Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol. 2016;73:535–41.CrossRefPubMedPubMedCentral
59.
Weintraub D, Chiang C, Kim HM, Wilkinson J, Marras C, Stanislawski B, et al. Antipsychotic use and physical morbidity in Parkinson disease. Am J Geriatr Psychiatry. 2017;25:697–705.CrossRefPubMed
60.
Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. BioMed Res Int. 2014;2014:656370.CrossRefPubMedPubMedCentral
61.
Fredericks D, Norton JC, Atchison C, Schoenhaus R, Pill MW. Parkinson’s disease and Parkinsons disease psychosis: a perspective on the challenges, treatments, and economic burden. Am J Manag Care. 2017;23:S83–92.PubMed
62.
Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–43.CrossRefPubMed
63.
Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology. 2010;35:881–92.CrossRefPubMed
64.
65.
Schapira AHV. Monoamine oxidase B inhibitors for the treatment of Parkinson’s disease: a review of symptomatic and potential disease-modifying effects. CNS Drugs. 2011;25:1061–71.CrossRefPubMed
66.
Cereda E, Cilia R, Canesi M, Tesei S, Mariani CB, Zecchinelli AL, et al. Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case–control study. J Neurol. 2017;264:1254–63.CrossRefPubMedPubMedCentral
67.
Kumagai T, Nagayama H, Ota T, Nishiyama Y, Mishina M, Ueda M. Sex differences in the pharmacokinetics of levodopa in elderly patients with Parkinson disease. Clin Neuropharmacol. 2014;37:173–6.CrossRefPubMed
68.
Nagayama H, Ueda M, Kumagai T, Tsukamoto K, Nishiyama Y, Nishimura S, et al. Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson’s disease. Parkinsonism Relat Disord. 2011;17:150–2.CrossRefPubMed
69.
Kanis JA, Cooper C, Rizzoli R, Reginster J-Y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30:3–44.CrossRefPubMed
70.
van den Bos F, Speelman AD, Samson M, Munneke M, Bloem BR, Verhaar HJJ. Parkinson’s disease and osteoporosis. Age Ageing. 2013;42:156–62.CrossRefPubMed
71.
Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson’s disease. Acta Neurol Scand. 2003;108:66–7.CrossRefPubMed
72.
73.
Szadejko K, Dziewiatowski K, Szabat K, Robowski P, Schinwelski M, Sitek E, et al. Polyneuropathy in levodopa-treated Parkinson’s patients. J Neurol Sci. 2016;371:36–41.CrossRefPubMed
74.
Loens S, Chorbadzhieva E, Kleimann A, Dressler D, Schrader C. Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy. Brain Behav. 2017;7:e00698.CrossRefPubMedPubMedCentral
75.
Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RMA. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2011;17:724–9.CrossRefPubMedPubMedCentral
76.
Ferrer-Gila T, Rizea C. Orthostatic hypotension in the elderly. Rev Neurol. 2013;56:337–43.PubMed
77.
Jost WH, Augustis S. Severity of orthostatic hypotension in the course of Parkinson’s disease: no correlation with the duration of the disease. Parkinsonism Relat Disord. 2015;21:314–6.CrossRefPubMed
78.
Noack C, Schroeder C, Heusser K, Lipp A. Cardiovascular effects of levodopa in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:815–8.CrossRef
79.
Kondo M, Ueda Y, Makino M, Nakajima K. Worsened orthostatic hypotension due to levodopa administration in a case of Parkinson’s disease. Nihon Ronen Igakkai Zasshi. 2000;37:255–8.CrossRefPubMed
80.
Merola A, Sawyer RP, Artusi CA, Suri R, Berndt Z, Lopez-Castellanos JR, et al. Orthostatic hypotension in Parkinson disease: impact on health care utilization. Parkinsonism Relat Disord. 2018;47:45–9.CrossRefPubMed
81.
Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Curr Treat Options Neurol. 2018;20:54.CrossRefPubMed
82.
Doi H, Sakakibara R, Sato M, Masaka T, Kishi M, Tateno A, et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson’s disease. J Neurol Sci. 2012;319:86–8.CrossRefPubMed
83.
Muller T, Erdmann C, Bremen D, Schmidt WE, Muhlack S, Woitalla D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol. 2006;29:61–7.CrossRefPubMed
84.
Heetun ZS, Quigley EMM. Gastroparesis and Parkinson’s disease: a systematic review. Parkinsonism Relat Disord. 2012;18:433–40.CrossRefPubMed
85.
Greene RJ, Hall AD, Hider RC. The interaction of orally administered iron with levodopa and methyldopa therapy. J Pharm Pharmacol. 1990;42:502–4.CrossRefPubMed
86.
Campbell NR, Hasinoff B. Ferrous sulfate reduces levodopa bioavailability: chelation as a possible mechanism. Clin Pharmacol Ther. 1989;45:220–5.CrossRefPubMed
87.
Deleu D, Jacob P, Chand P, Sarre S, Colwell A. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. Neurology. 2006;67:897–9.CrossRefPubMed
88.
Robertson DR, Higginson I, Macklin BS, Renwick AG, Waller DG, George CF. The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. Br J Clin Pharmacol. 1991;31:413–7.CrossRefPubMedPubMedCentral
89.
Simon N, Gantcheva R, Bruguerolle B, Viallet F. The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2004;10:137–42.CrossRefPubMed
90.
91.
Jenner P. Pharmacology of dopamine agonists in the treatment of Parkinson’s disease. Neurology. 2002;58(4 Suppl. 1):S1–8.CrossRefPubMed
92.
Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson’s disease. Clin Neuropharmacol. 1998;21:141–51.PubMed
93.
Chen JJ, Swope DM, Dashtipour K, Lyons KE. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson’s disease. Pharmacotherapy. 2009;29:1452–67.CrossRefPubMed
94.
Tulloch IF. Pharmacologic profile of ropinirole: a nonergoline dopamine agonist. Neurology. 1997;49(1 Suppl. 1):S58–62.CrossRefPubMed
95.
Hagell P, Odin P. Apomorphine in the treatment of Parkinson’s disease. J Neurosci Nurs. 2001;33(21–34):37–8.
96.
Stacy M, Silver D. Apomorphine for the acute treatment of “off” episodes in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14:85–92.CrossRefPubMed
97.
Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson’s disease: meta-analysis of randomized controlled trials. Drug Saf. 2010;33:147–61.CrossRefPubMed
98.
Voon V, Hassan K, Zurowski M, Duff-Canning S, de Souza M, Fox S, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology. 2006;66:1750–2.CrossRefPubMed
99.
Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology. 2006;67:1254–7.CrossRefPubMed
100.
Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63:969–73.CrossRefPubMedPubMedCentral
101.
Bienfait KL, Menza M, Mark MH, Dobkin RD. Impulsive smoking in a patient with Parkinson’s disease treated with dopamine agonists. J Clin Neurosci. 2010;17:539–40.CrossRefPubMedPubMedCentral
102.
Ceravolo R, Frosini D, Rossi C, Bonuccelli U. Impulse control disorders in Parkinson’s disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord. 2009;15(Suppl. 4):S111–5.CrossRefPubMed
103.
Miyasaki JM. Evidence-based initiation of dopaminergic therapy in Parkinson’s disease. J Neurol. 2010;257(Suppl. 2):S309–13.CrossRefPubMed
104.
Antonini A, Chaudhuri KR, Boroojerdi B, Asgharnejad M, Bauer L, Grieger F, et al. Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. Eur J Neurol. 2016;23:1556–65.CrossRefPubMedPubMedCentral
105.
Moller JC, Eggert KM, Unger M, Odin P, Chaudhuri KR, Oertel WH. Clinical risk-benefit assessment of dopamine agonists. Eur J Neurol. 2008;15(Suppl. 2):15–23.CrossRefPubMed
106.
Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov Disord. 2003;18:659–67.CrossRefPubMed
107.
Etminan M, Gill S, Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson’s disease: a meta-analysis. Drug Saf. 2003;26:439–44.CrossRefPubMed
108.
Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology. 2001;57:456–62.CrossRefPubMed
109.
Gao X, Chen H, Schwarzschild MA, Ascherio A. A prospective study of bowel movement frequency and risk of Parkinson’s disease. Am J Epidemiol. 2011;174:546–51.CrossRefPubMedPubMedCentral
110.
Zhou C-Q, Zhang J-W, Wang M, Peng G-G. Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson’s disease. J Clin Neurosci. 2014;21:1094–101.CrossRefPubMed
111.
Tan EK, Jankovic J. Choosing dopamine agonists in Parkinson’s disease. Clin Neuropharmacol. 2001;24:247–53.CrossRefPubMed
112.
Chaudhuri KR, Pal S, Brefel-Courbon C. ‘Sleep attacks’ or “unintended sleep episodes” occur with dopamine agonists: is this a class effect? Drug Saf. 2002;25:473–83.CrossRefPubMed
113.
Razmy A, Lang AE, Shapiro CM. Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. Arch. Neurol. 2004;61:97–102.CrossRefPubMed
114.
Sprenger FS, Seppi K, Poewe W. Drug safety evaluation of rotigotine. Expert Opin Drug Saf. 2012;11:503–12.CrossRefPubMed
115.
Ishiguro N, Saito A, Yokoyama K, Morikawa M, Igarashi T, Tamai I. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 2005;33:495–9.CrossRefPubMed
116.
Knop J, Hoier E, Ebner T, Fromm MF, Muller F. Renal tubular secretion of pramipexole. Eur J Pharm Sci. 2015;79:73–8.CrossRefPubMed
117.
Wu MJ, Ing TS, Soung LS, Daugirdas JT, Hano JE, Gandhi VC. Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clin Nephrol. 1982;17:19–23.PubMed
118.
Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet. 2000;39:243–54.CrossRefPubMed
119.
Bloomer JC, Clarke SE, Chenery RJ. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab Dispos. 1997;25:840–4.PubMed
120.
Girndt M, Trocchi P, Scheidt-Nave C, Markau S, Stang A. The prevalence of renal failure: results from the German Health Interview and Examination Survey for Adults, 2008–2011 (DEGS1). Dtsch Arztebl Int. 2016;113:85–91.PubMedPubMedCentral
121.
Schaeffner ES, Ebert N, Delanaye P, Frei U, Gaedeke J, Jakob O, et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med. 2012;157:471–81.CrossRefPubMed
122.
Pellecchia MT, Vitale C, Sabatini M, Longo K, Amboni M, Bonavita V, et al. Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clin Neuropharmacol. 2004;27:178–81.CrossRefPubMed
123.
Cawello W, Ahrweiler S, Sulowicz W, Szymczakiewicz-Multanowska A, Braun M. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function. Br J Clin Pharmacol. 2012;73:46–54.CrossRefPubMedPubMedCentral
124.
Cieslak KP, Baur O, Verheij J, Bennink RJ, van Gulik TM. Liver function declines with increased age. HPB (Oxford). 2016;18:691–6.CrossRef
125.
Cawello W, Fichtner A, Boekens H, Braun M. Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine. Eur J Drug Metab Pharmacokinet. 2014;39:155–63.CrossRefPubMed
126.
Navacerrada F, Gonzalez-Alonso MR, Alonso-Navarro H, Pilo-de-la-Fuente B, Plaza-Nieto JF, Jimenez-Jimenez FJ. Liver toxicity possibly related with ropinirole use in the treatment of restless legs syndrome. Eur J Neurol. 2011;18:e65.CrossRefPubMed
127.
Dewey RBJ, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol. 2001;58:1385–92.CrossRefPubMed
128.
Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet. 1988;1:403–6.CrossRefPubMed
129.
Humphrey SJ, Turman CN, Curry JT, Wheeler GJ. Cardiovascular and electrocardiographic effects of the dopamine receptor agonists ropinirole, apomorphine, and PNU-142774E in conscious beagle dogs. J Cardiovasc Pharmacol. 2006;47:337–47.PubMed
130.
Stocchi F, De Pandis MF, Delfino FA, Anselmo T, Frongillo D. Transient atrial fibrillation after subcutaneous apomorphine bolus. Mov Disord. 1996;11:584–5.CrossRefPubMed
131.
Kaminioti AN, Nikitas GT, Terlis AK, Manolis AG, Thomaides T, Panousopoulou AN. Ventricular bigeminy after subcutaneous administration of apomorphine in a patient with refractory Parkinson’s disease: a case report. J Mov Disord. 2013;6:9–12.CrossRefPubMedPubMedCentral
132.
Sartori M, Pratt CM, Young JB. Torsade de Pointe. Malignant cardiac arrhythmia induced by amantadine poisoning. Am J Med. 1984;77:388–91.CrossRefPubMed
133.
134.
De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf. 2002;25:263–86.CrossRefPubMed
135.
Watanabe Y, Nakamura Y, Cao X, Ohara H, Yamazaki Y, Murayama N, et al. Intravenous administration of apomorphine does NOT induce long QT syndrome: experimental evidence from in vivo canine models. Basic Clin Pharmacol Toxicol. 2015;116:468–75.CrossRefPubMed
136.
Halvorsen KA, Martensen-Larsen O. Apomorphine revived: fortified, prolonged, and improved therapeutical effect. Int J Addict. 1978;13:475–84.CrossRefPubMed
137.
138.
Rausten DS, Ochs MA. Apomorphine-naloxone controlled rapid emesis. J Am Coll Emerg Phys. 1973;2:44–5.CrossRef
139.
Björklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007;30:194–202.CrossRefPubMed
140.
Muller T. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs. 2015;75:157–74.CrossRefPubMed
141.
Axelrod J, Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem. 1958;233:702–5.PubMed
142.
Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev. 1975;27:135–206.PubMed
143.
Napolitano A, Del Dotto P, Petrozzi L, Dell’Agnello G, Bellini G, Gambaccini G, et al. Pharmacokinetics and pharmacodynamics of l-Dopa after acute and 6-week tolcapone administration in patients with Parkinson’s disease. Clin Neuropharmacol. 1999;22:24–9.CrossRefPubMed
144.
Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson’s disease. Clin Neuropharmacol. 1996;19:283–96.CrossRefPubMed
145.
Ferreira JJ, Lees A, Rocha J-F, Poewe W, Rascol O, Soares-da-Silva P. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016;15:154–65.CrossRef
146.
Factor SA, Molho ES, Feustel PJ, Brown DL, Evans SM. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson’s disease. Clin Neuropharmacol. 2001;24:295–9.CrossRefPubMed
147.
Rocha J-F, Almeida L, Falcao A, Palma PN, Loureiro AI, Pinto R, et al. Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol. 2013;76:763–75.CrossRefPubMedPubMedCentral
148.
Davis TL, Roznoski M, Burns RS. Effects of tolcapone in Parkinson’s patients taking l-dihydroxyphenylalanine/carbidopa and selegiline. Mov Disord. 1995;10:349–51.CrossRefPubMed
149.
Kuoppamaki M, Leinonen M, Poewe W. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off. J Neural Transm (Vienna). 2015;122:1709–14.CrossRef
150.
Rodrigues FB, Ferreira JJ. Opicapone for the treatment of Parkinson’s disease. Expert Opin Pharmacother. 2017;18:445–53.CrossRefPubMed
151.
Antonini A, Abbruzzese G, Barone P, Bonuccelli U, Lopiano L, Onofrj M, et al. COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features. Neuropsychiatr Dis Treat. 2008;4:1–9.CrossRefPubMedPubMedCentral
152.
Suchowersky O, Bailey P, Pourcher E, Bulger L, Facciponte G. Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD. Clin Neuropharmacol. 2001;24:214–20.CrossRefPubMed
153.
Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol. 2007;30:287–94.CrossRefPubMed
154.
Lees AJ, Ratziu V, Tolosa E, Oertel WH. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78:944–8.CrossRefPubMed
155.
Unger MM, Reese JP, Oertel WH, Eggert KM. Real-life evaluations of compliance with mandatory drug safety monitoring exemplified with tolcapone in Parkinson’s disease. Eur Neurol. 2008;60:122–6.CrossRefPubMed
156.
Heranval A, Lefaucheur R, Fetter D, Rouille A, Le Goff F, Maltete D. Drugs with potential cardiac adverse effects: retrospective study in a large cohort of parkinsonian patients. Rev Neurol (Paris). 2016;172:318–23.CrossRef
157.
Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, et al. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010;20:277–81.PubMedPubMedCentral
158.
Dingemanse J, Meyerhoff C, Schadrack J. Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. Br J Clin Pharmacol. 2002;53:485–91.CrossRefPubMedPubMedCentral
159.
European Medicines Agency. Ongentys: EMA assessment report. London, UK: European Medicines Agency; 2016. p. 1–140.
160.
Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos. 2013;34:45–78.CrossRefPubMed
161.
Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I. Intestinal drug interactions mediated by OATPs: a systematic review of preclinical and clinical findings. J Pharm Sci. 2017;106:2312–25.CrossRefPubMed
162.
Kalgutkar AS, Dalvie DK, Castagnoli NJ, Taylor TJ. Interactions of nitrogen-containing xenobiotics with monoamine oxidase (MAO) isozymes A and B: SAR studies on MAO substrates and inhibitors. Chem Res Toxicol. 2001;14:1139–62.CrossRefPubMed
163.
Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson’s disease. Pharmacotherapy. 2007;27:174S–85S.CrossRefPubMed
164.
Chang Y, Wang L-B, Li D, Lei K, Liu S-Y. Efficacy of rasagiline for the treatment of Parkinson’s disease: an updated meta-analysis. Ann Med. 2017;49:421–34.CrossRefPubMed
165.
Dashtipour K, Chen JJ, Kani C, Bahjri K, Ghamsary M. Clinical outcomes in patients with Parkinson’s disease treated with a monoamine oxidase type-B inhibitor: a cross-sectional, cohort study. Pharmacotherapy. 2015;35:681–6.CrossRefPubMedPubMedCentral
166.
Dezsi L, Vecsei L. Monoamine oxidase B inhibitors in Parkinson’s disease. CNS Neurol Disord Drug Targets. 2017;16:425–39.CrossRefPubMed
167.
Riederer P, Lachenmayer L. Selegiline’s neuroprotective capacity revisited. J Neural Transm (Vienna). 2003;110:1273–8.CrossRef
168.
Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 2009;361:1268–78.CrossRefPubMed
169.
Sadeghian M, Mullali G, Pocock JM, Piers T, Roach A, Smith KJ. Neuroprotection by safinamide in the 6-hydroxydopamine model of Parkinson’s disease. Neuropathol Appl Neurobiol. 2016;42:423–35.CrossRefPubMed
170.
Hauser RA, Abler V, Eyal E, Eliaz RE. Efficacy of rasagiline in early Parkinson’s disease: a meta-analysis of data from the TEMPO and ADAGIO studies. Int J Neurosci. 2016;126:942–6.CrossRefPubMed
171.
Jenner P, Langston JW. Explaining ADAGIO: a critical review of the biological basis for the clinical effects of rasagiline. Mov Disord. 2011;26:2316–23.CrossRefPubMed
172.
Romberg RW, Needleman SB, Snyder JJ, Greedan A. Methamphetamine and amphetamine derived from the metabolism of selegiline. J Forensic Sci. 1995;40:1100–2.CrossRefPubMed
173.
Stocchi F, Torti M. Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide. Drug Des Dev Ther. 2016;10:609–18.CrossRef
174.
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937–43.CrossRef
175.
Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, et al. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci. 2006;248:78–83.CrossRefPubMed
176.
Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med. 1993;328:176–83.CrossRef
177.
Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson’s disease. Mov Disord. 2014;29:1028–34.CrossRefPubMed
178.
Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease in Parkinson Study Group. Neurology. 1997;48:1070–7.CrossRefPubMed
179.
Panisset M, Chen JJ, Rhyee SH, Conner J, Mathena J. Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy. 2014;34:1250–8.CrossRefPubMed
180.
Aboukarr A, Giudice M. Interaction between monoamine oxidase B inhibitors and selective serotonin reuptake inhibitors. Can J Hosp Pharm. 2018;71:196–207.PubMedPubMedCentral
181.
Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006;43:180–7.CrossRefPubMed
182.
Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol. 2005;45:878–94.CrossRefPubMed
183.
Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;63:228–34.CrossRefPubMedPubMedCentral
184.
Laine K, Anttila M, Helminen A, Karnani H, Huupponen R. Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids. Br J Clin Pharmacol. 1999;47:249–54.CrossRefPubMedPubMedCentral
185.
Palovaara S, Anttila M, Nyman L, Laine K. Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline. Eur J Clin Pharmacol. 2002;58:259–63.CrossRefPubMed
186.
Cruz MP. Xadago (Safinamide): a monoamine oxidase B inhibitor for the adjunct treatment of motor symptoms in Parkinson’s disease. P T. 2017;42:622–37.PubMedPubMedCentral
187.
Finberg JPM. Pharmacology of rasagiline, a new MAO-B inhibitor drug for the treatment of Parkinson’s disease with neuroprotective potential. Rambam Maimonides Med J. 2010;1:e0003.CrossRefPubMedPubMedCentral
188.
Chen JJ, Wilkinson JR. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge? J Clin Pharmacol. 2012;52:620–8.CrossRefPubMed
189.
Marquet A, Kupas K, Johne A, Astruc B, Patat A, Krosser S, et al. The effect of safinamide, a novel drug for Parkinson’s disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. Clin Pharmacol Ther. 2012;92:450–7.PubMed
190.
Anttila M, Sotaniemi EA, Pelkonen O, Rautio A. Marked effect of liver and kidney function on the pharmacokinetics of selegiline. Clin Pharmacol Ther. 2005;77:54–62.CrossRefPubMed
191.
Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508–13.CrossRefPubMed
192.
Aizenberg D, Sigler M, Weizman A, Barak Y. Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4-year case–control study. Int Psychogeriatr. 2002;14:307–10.CrossRefPubMed
193.
Ehrt U, Broich K, Larsen JP, Ballard C, Aarsland D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study. J Neurol Neurosurg Psychiatry. 2010;81:160–5.CrossRefPubMed
194.
Crispo JAG, Willis AW, Thibault DP, Fortin Y, Hays HD, McNair DS, et al. Associations between anticholinergic burden and adverse health outcomes in Parkinson disease. PLoS One. 2016;11:e0150621.CrossRefPubMedPubMedCentral
195.
Vezina P, Mohr E, Grimes D. Deprenyl in Parkinson’s disease: mechanisms, neuroprotective effect, indications and adverse effects. Can J Neurol Sci. 1992;19:142–6.CrossRefPubMed
196.
Glavin GB, Dugani AM, Pinsky C. L-deprenyl attenuates stress ulcer formation in rats. Neurosci Lett. 1986;70:379–81.CrossRefPubMed
197.
Geyer M, Stamenic I, Buhler H, Bertschinger P. Epidemiology of gastrointestinal bleeding in the elderly. Praxis (Bern 1994). 2006;95:757–65.CrossRef
198.
Kyaw MH, Chan FKL. Pharmacologic options in the management of upper gastrointestinal bleeding: focus on the elderly. Drugs Aging. 2014;31:349–61.CrossRefPubMed
199.
Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakanishi S. Molecular cloning and characterization of the rat NMDA receptor. Nature. 1991;354:31–7.CrossRefPubMed
200.
201.
Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78:1096–9.CrossRefPubMed
202.
Schwab RS, England ACJ, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson’s disease. JAMA. 1969;208:1168–70.CrossRefPubMed
203.
Mizoguchi K, Yokoo H, Yoshida M, Tanaka T, Tanaka M. Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-d-aspartate antagonism. Brain Res. 1994;662:255–8.CrossRefPubMed
204.
Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD, et al. ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (EASE LID Study): a randomized clinical trial. JAMA Neurol. 2017;74:941–9.CrossRefPubMedPubMedCentral
205.
Oertel W, Eggert K, Pahwa R, Tanner CM, Hauser RA, Trenkwalder C, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord. 2017;32:1701–9.CrossRefPubMedPubMedCentral
206.
Hiraoka M, Hirano Y, Kawano S, Fan Z, Sawanobori T. Amantadine-induced afterpotentials and automaticity in guinea pig ventricular myocytes. Circ Res. 1989;65:880–93.CrossRefPubMed
207.
Manini AF, Raspberry D, Hoffman RS, Nelson LS. QT prolongation and torsades de pointes following overdose of ziprasidone and amantadine. J Med Toxicol. 2007;3:178–81.CrossRefPubMedPubMedCentral
208.
209.
Akturk IF, Erol MK. Bradyarrhythmias and pacemaker indications in elderly patients. Turk Kardiyol Dern Ars. 2017;45:71–4.PubMed
210.
Dandamudi S, Slusser J, Mahoney DW, Redfield MM, Rodeheffer RJ, Chen HH. The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota. J Card Fail. 2014;20:304–9.CrossRefPubMedPubMedCentral
211.
Nakata M, Ito S, Shirai W, Hattori T. Severe reversible neurological complications following amantadine treatment in three elderly patients with renal insufficiency. Eur Neurol. 2006;56:59–61.CrossRefPubMed
212.
Bleidner WE, Harmon JB, Hewes WE, Lynes TE, Hermann EC. Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther. 1965;150:484–90.PubMed
213.
Ing TS, Rahn AC, Armbruster KF, Oyama JH, Klawans HL. Letter: accumulation of amantadine hydrochloride in renal insufficiency. N Engl J Med. 1974;291:1257.PubMed
214.
Stoof JC, Booij J, Drukarch B, Wolters EC. The anti-parkinsonian drug amantadine inhibits the N-methyl-d-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol. 1992;213:439–43.CrossRefPubMed
215.
Lupp A, Lucking CH, Koch R, Jackisch R, Feuerstein TJ. Inhibitory effects of the antiparkinsonian drugs memantine and amantadine on N-methyl-d-aspartate-evoked acetylcholine release in the rabbit caudate nucleus in vitro. J Pharmacol Exp Ther. 1992;263:717–24.PubMed
216.
217.
Neagoe AD. Delirium with manic and psychotic features associated with amantadine. Gen Hosp Psychiatry. 2013;35(680):e7–8.
218.
Postma JU, Van Tilburg W. Visual hallucinations and delirium during treatment with amantadine (Symmetrel). J Am Geriatr Soc. 1975;23:212–5.CrossRefPubMed
219.
Flaherty JA, Bellur SN. Mental side effects of amantadine therapy: its spectrum and characteristics in a normal population. J Clin Psychiatry. 1981;42:344–5.PubMed
220.
221.
Moreno O, Garcia PT, Sanchez D, Sancho T, Lecumberri B. Cognitive impairment and severe hypocalcemia in a patient with hypoparathyroidism and systemic sclerosis: report of a case. Endocrinol Nutr. 2015;62:356–8.CrossRefPubMed
222.
Fujioka S, Fukae J, Ogura H, Mishima T, Yanamoto S, Higuchi M-A, et al. Hospital-based study on emergency admission of patients with Parkinson’s disease. eNeurologicalSci. 2016;4:19–21.CrossRefPubMedPubMedCentral
223.
224.
Braga M, Pederzoli M, Antonini A, Beretta F, Crespi V. Reasons for hospitalization in Parkinson’s disease: a case–control study. Parkinsonism Relat Disord. 2014;20:488–92.CrossRefPubMed
225.
Begg DP. Disturbances of thirst and fluid balance associated with aging. Physiol Behav. 2017;178:28–34.CrossRefPubMed
226.
Hindle JV. The practical management of cognitive impairment and psychosis in the older Parkinson’s disease patient. J Neural Transm (Vienna). 2013;120:649–53.CrossRef
227.
228.
Mokhles MM, Trifiro G, Dieleman JP, Haag MD, van Soest EM, Verhamme KMC, et al. The risk of new onset heart failure associated with dopamine agonist use in Parkinson’s disease. Pharmacol Res. 2012;65:358–64.CrossRefPubMed
229.
Hasenfuss G, Kasper W, Meinertz T, Busch W, Lehmann M, Krause T, et al. Evaluation of long-term oral levodopa therapy in chronic congestive heart failure. Klin Wochenschr. 1987;65:1087–94.CrossRefPubMed
230.
Montastruc JL, Rascol O, Montastruc P. Naloxone or haloperidol but not yohimbine reverse apomorphine-induced respiratory depression. Clin Neuropharmacol. 1992;15:404–7.CrossRefPubMed
231.
Srinivasan M, Lagercrantz H, Yamamoto Y. A possible dopaminergic pathway mediating hypoxic depression in neonatal rabbits. J Appl Physiol. 1985;1989(67):1271–6.
232.
Gibbons CH, Simon DK, Huang M, Tilley B, Aminoff MJ, Bainbridge JL, et al. Autonomic and electrocardiographic findings in Parkinson’s disease. Auton Neurosci. 2017;205:93–8.CrossRefPubMedPubMedCentral
233.
Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol. 2007;22:39–43.CrossRefPubMed
234.
235.
Jahn K, Kressig RW, Bridenbaugh SA, Brandt T, Schniepp R. Dizziness and unstable gait in old age: etiology, diagnosis and treatment. Dtsch Arztebl Int. 2015;112:387–93.PubMedPubMedCentral
236.
Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol. 2016;31:5–20.CrossRefPubMed
237.
Nyholm D, Nilsson Remahl AIM, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64:216–23.CrossRefPubMed
238.
239.
Krause O, Wiese B, Doyle I-M, Kirsch C, Thürmann P, Wilm S, et al. Multidisciplinary intervention to improve medication safety in nursing home residents: protocol of a cluster randomised controlled trial (HIOPP-3-iTBX study). BMC Geriatr. 2019;19:24.CrossRefPubMedPubMedCentral
240.
Lange R, Erbguth F. Parkinson’s disease in the elderly. Z Gerontol Geriatr. 2017;50:547–59.CrossRefPubMed
241.
Yildirim AB, Kilinc AY. Polypharmacy and drug interactions in elderly patients. Turk Kardiyol Dern Ars. 2017;45:17–21.PubMed
242.
Moriarty F, Hardy C, Bennett K, Smith SM, Fahey T. Trends and interaction of polypharmacy and potentially inappropriate prescribing in primary care over 15 years in Ireland: a repeated cross-sectional study. BMJ Open. 2015;5:e008656.CrossRefPubMedPubMedCentral
243.
Muhic N, Mrhar A, Brvar M. Comparative analysis of three drug–drug interaction screening systems against probable clinically relevant drug–drug interactions: a prospective cohort study. Eur J Clin Pharmacol. 2017;73:875–82.CrossRefPubMed
244.
Somogyi-Vegh A, Nyaka B, Vida RG, Lovasz A, Botz L. Comprehensive evaluation of drug interaction screening programs: discrepancies and concordances. Orv Hetil. 2015;156:720–30.CrossRefPubMed
245.
Kheshti R, Aalipour M, Namazi S. A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016;5:257–63.CrossRefPubMedPubMedCentral
246.
Moura CS, Prado NM, Belo NO, Acurcio FA. Evaluation of drug–drug interaction screening software combined with pharmacist intervention. Int J Clin Pharm. 2012;34:547–52.CrossRefPubMed
247.
Pazan F, Weiss C, Wehling M. The FORTA (Fit fOR The Aged) List 2015: update of a validated clinical tool for improved pharmacotherapy in the elderly. Drugs Aging. 2016;33:447–9.CrossRefPubMed
248.
Kuhn-Thiel AM, Weiss C, Wehling M. Consensus validation of the FORTA (Fit fOR The Aged) List: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging. 2014;31:131–40.CrossRefPubMed
249.
Brown JD, Hutchison LC, Li C, Painter JT, Martin BC. Predictive validity of the Beers and Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions (STOPP) criteria to detect adverse drug events, hospitalizations, and emergency department visits in the United States. J Am Geriatr Soc. 2016;64:22–30.CrossRefPubMedPubMedCentral
250.
Hamilton H, Gallagher P, Ryan C, Byrne S, O’Mahony D. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 2011;171:1013–9.CrossRefPubMed
251.
Siebert S, Elkeles B, Hempel G, Kruse J, Smollich M. The PRISCUS list in clinical routine: practicability and comparison to international PIM lists. Z Gerontol Geriatr. 2013;46:35–47.CrossRefPubMed
252.
Cooper JA, Cadogan CA, Patterson SM, Kerse N, Bradley MC, Ryan C, et al. Interventions to improve the appropriate use of polypharmacy in older people: a Cochrane systematic review. BMJ Open. 2015;5:e009235.CrossRefPubMedPubMedCentral
253.
Kim J, Parish AL. Polypharmacy and medication management in older adults. Nurs Clin North Am. 2017;52:457–68.CrossRefPubMed
254.
O’Mahony D, O’Ullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8.CrossRefPubMed
255.
Salbu RL, Feuer J. A closer look at the 2015 Beers criteria. J Pharm Pract. 2017;30:419–24.CrossRefPubMed
256.
Antimisiaris D, Cutler T. Managing polypharmacy in the 15-minute office visit. Prim Care. 2017;44:413–28.CrossRefPubMed
257.
Jansen J, Naganathan V, Carter SM, McLachlan AJ, Nickel B, Irwig L, et al. Too much medicine in older people? Deprescribing through shared decision making. BMJ. 2016;353:i2893.CrossRefPubMed
258.
Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175:827–34.CrossRefPubMed
259.
Loffler C, Drewelow E, Paschka SD, Frankenstein M, Eger J, Jatsch L, et al. Optimizing polypharmacy among elderly hospital patients with chronic diseases: study protocol of the cluster randomized controlled POLITE-RCT trial. Implement Sci. 2014;9:151.CrossRefPubMedPubMedCentral
Metadaten
Titel
Safety and Tolerability of Pharmacotherapies for Parkinson’s Disease in Geriatric Patients
verfasst von
Martin Klietz
Stephan Greten
Florian Wegner
Günter U. Höglinger
Publikationsdatum
02.04.2019
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 6/2019
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-019-00654-z

Weitere Artikel der Ausgabe 6/2019

Drugs & Aging 6/2019 Zur Ausgabe

Original Research Article

Adjuvant Use and the Intensification of Pharmacologic Management for Pain in Nursing Home Residents with Cancer: Data from a US National Database

Short Communication

Safety and Pharmacokinetics of Levobupivacaine Following Fascia Iliaca Compartment Block in Elderly Patients

Original Research Article

A Point Prevalence Study of Antimicrobial Use and Practice Among Nursing Homes in Singapore

Review Article

Elderly Patients with ST-Segment Elevation Myocardial Infarction: A Patient-Centered Approach

Leading Article

Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options

Review Article

Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise